{"classes":[{"categories":[{"measurements":[{"comment":"The 90% confidence interval was not estimable due to single participant.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"35.0"},{"comment":"The 90% confidence interval was not estimable due to single participant.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"16.4"},{"comment":"The upper limit of 90% confidence interval was not estimable due to an insufficient number of participants with events.","groupId":"OG002","lowerLimit":"13.4","upperLimit":"NA","value":"52.4"},{"comment":"The upper limit of 90% confidence interval was not estimable due to an insufficient number of participants with events.","groupId":"OG003","lowerLimit":"13.9","upperLimit":"NA","value":"37.9"},{"groupId":"OG004","lowerLimit":"17.9","upperLimit":"79.3","value":"46.0"},{"comment":"The median and upper limit of 90% confidence interval were not estimable due to an insufficient number of participants with events.","groupId":"OG005","lowerLimit":"17.4","upperLimit":"NA","value":"NA"},{"comment":"The median and upper limit of 90% confidence interval were not estimable due to an insufficient number of participants with events.","groupId":"OG006","lowerLimit":"11.6","upperLimit":"NA","value":"NA"},{"comment":"The upper limit of 90% confidence interval was not estimable due to an insufficient number of participants with events.","groupId":"OG007","lowerLimit":"9.4","upperLimit":"NA","value":"12.5"},{"comment":"The upper limit of 90% confidence interval was not estimable due to an insufficient number of participants with events.","groupId":"OG008","lowerLimit":"7.6","upperLimit":"NA","value":"14.1"},{"comment":"The upper limit of 90% confidence interval was not estimable due to an insufficient number of participants with events.","groupId":"OG009","lowerLimit":"18.7","upperLimit":"NA","value":"23.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"13"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"8"},{"groupId":"OG009","value":"31"}],"units":"Participants"}],"description":"OS was measured from the time from the first dose of study drug until the date of death due to any cause.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received TAK-186, Dose A as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose A is the lowest dose.","id":"OG000","title":"Dose Escalation Phase: TAK-186 - Dose A + Dexamethasone"},{"description":"Participants received TAK-186, Dose B as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose B is higher than Dose A.","id":"OG001","title":"Dose Escalation Phase: TAK-186 -Dose B + Dexamethasone"},{"description":"Participants received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose C is higher than Dose B.","id":"OG002","title":"Dose Escalation Phase: TAK-186 -Dose B → Dose C + Dexamethasone"},{"description":"Participants received TAK-186, Dose B on Day 1 followed by Dose D on Day 8 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose D is higher than Dose B.","id":"OG003","title":"Dose Escalation Phase: TAK-186 - Dose B → Dose D + Dexamethasone"},{"description":"Participants received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and Dose E on Day 15 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose E is higher than Dose C and B.","id":"OG004","title":"Dose Escalation Phase: TAK-186 - Dose B → Dose C→ Dose E + Dexamethasone"},{"description":"Participants received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and Dose E on Day 15 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion and post-infusion. Dose E is higher than Dose C and B.","id":"OG005","title":"Dose Escalation Phase: TAK-186 - Dose B → Dose C→ Dose E + Double Dexamethasone"},{"description":"Participants received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and Dose F on Day 15 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose F is highest dose and is higher than Dose B and C.","id":"OG006","title":"Dose Escalation Phase: TAK-186 - Dose B → Dose C→ Dose F + Dexamethasone"},{"description":"Participants received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and Dose D on Day 15 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose D is higher than Dose B and C.","id":"OG007","title":"Dose Escalation Phase: TAK-186 - Dose B → Dose C→ Dose D + Dexamethasone"},{"description":"Participants received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and Dose D on Day 15 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion and post-infusion. Dose D is higher than Dose B and C.","id":"OG008","title":"Dose Escalation Phase:TAK-186 - Dose B → Dose C→ Dose D + Double Dexamethasone"},{"description":"Participants with NSCLC received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and Dose E on Day 15 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion and post-infusion. Dose E is higher than Dose C and B.","id":"OG009","title":"Cohort Expansion Phase: NSCLC"}],"paramType":"MEDIAN","populationDescription":"Safety population included all participants who received at least 1 dose of TAK-186.","reportingStatus":"POSTED","timeFrame":"From start of study drug up to end of study (up to 22 months)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"weeks"}